Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci094 + hCG in Adolescent Males with Idiopathic Hypogonadotropic Hypogonadism
NCT06561594Phase 3Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Nov 2024
- Modality
- rProtein (Recombinant Protein), Hormone, Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of corifollitropin alfa in idiopathic hypogonadotropic hypogonadism (IHH) (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in testicular volume at 64 weeks. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
corifollitropin alfa
03
Conditions
idiopathic hypogonadotropic hypogonadism (IHH)
Beyond the preview
Go deeper on NCT06561594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561594.